Astegolimab and the new era of biologics in COPD care.

# Epub 2026 May 18. *Review Article* Astegolimab and the new era of biologics in COPD care. Leung C(1), Sin DD(2). Author information: (1)Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada; Centre for Heart Lung Innovation, St Paul's Hospital, University of British Columbia, Vancouver, BC V6Z 1Y6, Canada; Division of Pulmonary Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada. (2)Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada; Centre for Heart Lung Innovation, St Paul's Hospital, University of British Columbia, Vancouver, BC V6Z 1Y6, Canada; Division of Pulmonary Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada. Electronic address: don.sin@hli.ubc.ca. DOI: 10.1016/S0140-6736(26)00924-4 PMID: 42150580 Conflict of interest statement: In the past 3 years, CL has received a small honorarium from AstraZeneca for giving a talk on asthma to a group of physicians; however, AstraZeneca had no input on the content of the presentation. DS has received a small honorarium from AstraZeneca and GSK for giving a talk on chronic obstructive pulmonary disease (COPD) to a group of physicians; however, neither AstraZeneca nor GSK had any input on the content of the presentation. DS is a chair of a data safety monitoring board for a US National Institutes of Health-sponsored clinical trial on COPD, and is a Tier 1 Canada Research Chair in COPD. --- DOI: 10.1016/S0140-6736(26)00924-4